Comparative Pharmacology
Head-to-head clinical analysis: GENTAK versus PAROMOMYCIN SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GENTAK versus PAROMOMYCIN SULFATE.
GENTAK vs PAROMOMYCIN SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gentamicin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit of susceptible bacteria, causing misreading of mRNA and inhibiting protein synthesis, leading to bacterial cell death.
Paromomycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibition of protein synthesis in susceptible bacteria. It also has direct amebicidal activity against Entamoeba histolytica by inhibiting protein synthesis.
Gentamicin 3-5 mg/kg IV or IM once daily; alternatively, 1.5-2.5 mg/kg IV or IM every 8 hours.
25-35 mg/kg/day orally in 3 divided doses for 5-10 days for intestinal amebiasis; 1 g orally every 8 hours for 7 days for cryptosporidiosis.
None Documented
None Documented
2–3 hours in adults with normal renal function; prolonged to 24–60 hours in severe renal impairment (CrCl <10 mL/min).
Terminal elimination half-life: 2–3 hours in normal renal function; extends to 24–48 hours or longer in severe renal impairment, necessitating dose adjustment.
Renal excretion of unchanged drug accounts for >90% of elimination; <5% biliary/fecal.
Primarily renal excretion of unchanged drug via glomerular filtration; >90% of absorbed dose excreted in urine within 24 hours; negligible biliary/fecal elimination.
Category C
Category A/B
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic